BOTTNEURO
Bottneuro offers a unique, non-invasive therapy for early- and moderate-stage Alzheimer's Disease patients using electrical stimulations of neurons and glia cells in the brain. Bottoneuro develops stimulation protocols using the NENI technology platform.
BOTTNEURO
Industry:
Health Care Therapeutics
Founded:
2021-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.bottneuro.ch
Total Employee:
11+
Status:
Active
Contact:
+41 61 633 29 50
Email Addresses:
[email protected]
Total Funding:
150 K CHF
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
Venture Kick
Venture Kick investment in Grant - Bottneuro
Official Site Inspections
http://www.bottneuro.ch
- Host name: server51.hostfactory.ch
- IP address: 185.117.169.194
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Bottneuro"
Bottneuro AG | Leading provider of diagnosis and treatment of AD
Founded in 2021, Bottneuro AG is a cutting-edge medtech startup focused on improving the diagnosis and treatment of neurological diseases. As a spin-off from the University of Basel, …See details»
Bottneuro - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +41 61 633 29 50 Bottneuro offers a unique, non-invasive therapy for early- and moderate-stage …See details»
Investors - Bottneuro
Jul 8, 2021 Where is Bottneuro located? Bottneuro AG, a spin-off of the University of Basel, is located on the Novartis Campus, Lichtstrasse 35, 4056 Basel, Switzerland. ...See details»
Bottneuro AG - StiftungSchweiz
Bottneuro ist ein Startup der Universität Basel mit Sitz auf dem Novartis Campus. Wir entwickeln eine komplett personalisierte Neurostimulationstherapie für Alzheimerpatient:innen. Die …See details»
Bottneuro AG - top100startup.ch
15.12.2022 Bottneuro secures CHF 4 million to develop its non-invasive Alzheimer's treatment (venturekick.ch) 15.12.2022 CHF 4 million for Bottneuro (startupticker.ch) 12.12.2022 IMD …See details»
Bottneuro AG - Venture Kick
Jun 9, 2024 Bottneuro AG: Bottneuro, a startup from the University of Basel on the Novartis campus, provides a fully personalized neurostimulation therapy based on each patient's MRI data. ... 08.01.2024 Bottneuro advances into the …See details»
Bottneuro AG - LinkedIn
Bottneuro AG | 1,940 followers on LinkedIn. Precision medicine for brain health | About Bottneuro: At Bottneuro, we are pioneering the future of personalized neurological care with a strong focus ...See details»
Bottneuro AG: 3D-printed, patient-specific therapy for …
Bottneuro is developing a non-invasive, home-based therapy system for AD patients, using personalized transcranial electrical stimulation of selected brain areas. Our innovative method consists of periodic brain stimulation sessions, …See details»
Contact. Bottneuro Switzerland. Digital solutions for …
Bottneuro (Switzerland) is a spin-off of the University of Basel working on digital diagnostic solutions and non-invasive treatments for Alzheimer’s Disease (AD). Contact us! ... Bottneuro AG. Lichtstrasse 35 CH - 4056, Basel +41 61 515 00 …See details»
New DBE Spin-Off: Bottneuro AG - unibas.ch
Jan 25, 2021 A new spin-off called Bottneuro AG was founded on January 8, 2021. Its team develops plant-based, ultra-thin neural implants for the spine and brain under the leadership of …See details»
CHF 150,000 to advance personalized therapies for Alzheimer’s …
Dec 20, 2021 Bottneuro will fabricate the first series of 100 devices and start clinical trials in 2022; the first PET scan centers will be established in 2023. To support these plans, a CHF 10 …See details»
Bottneuro secures CHF 4 million to develop its non-invasive …
Dec 15, 2022 The startup, which is developing a non-invasive, home-based treatment for early- and moderate-stage Alzheimer's patients, closed the first tranche of the bridge round, bringing …See details»
A non-invasive, home-based treatment for AD patients - Bottneuro
Bottneuro is working on a non-invasive, home-based treatment for early- and moderate-stage AD patients using personalized electrical stimulations of glia cells in the brain ...See details»
Bottneuro AG - startup.ch
Bottneuro, a startup from the University of Basel on the Novartis campus, provides a fully personalized neurostimulation therapy based on each patient's MRI data. Our device is …See details»
Bottneuro advances into the clinical phase - startupticker.ch
Aug 1, 2024 startupticker.ch; Hirschmattstrasse 33; CH-6003 Luzern; Tel: +41 41 226 20 80; Fax: +41 41 226 20 89; [email protected]; Submit an event; Submit special offer; Login …See details»
CHF 4 million for Bottneuro - startupticker.ch
Dec 15, 2022 CH-6003 Luzern; Tel: +41 41 226 20 80; Fax: +41 41 226 20 89; [email protected]; Submit an event; Submit special offer; Login Register. Cancel Forgot …See details»
Digital solutions for Alzheimer’s patients - Bottneuro
Aug 12, 2024 Bottneuro AG is a spin-off of the University of Basel working on digital diagnostic solutions and non-invasive treatments for Alzheimer’s Disease (AD). Discover more ...See details»
Bottneuro wins CHF 150,000 to advance diagnosis and digital …
Dec 17, 2021 Bottneuro will facilitate the early-stage diagnosis of Alzheimer’s disease (AD) and aims to become a leading provider of personalized digital therapies for AD. The Basel-based …See details»
Bottneuro wins CHF 150,000 to advance diagnosis and digital …
Dec 17, 2021 To support these plans, a CHF 10 million Series A is planned for 2022 and 2023. The Venture Kick funds, complemented by a Kick Fund investment, will lay the foundation for …See details»